Pharming Group NV (OTCMKTS:PHGUF) Sees Significant Increase in Short Interest

Key Points

• Pharming Group NV experienced a significant increase in short interest, rising by 98.5% from mid-July to July 31st, totaling 4,952,300 shares.
• The company's stock price remained flat at $1.16, with a 12-month low of $0.75 and a high of $1.19.
• Pharming Group develops therapies for rare diseases and offers RUCONEST for hereditary angioedema and Joenja for activated PI3K delta syndrome.

Pharming Group NV (OTCMKTS:PHGUF - ) was the target of a significant increase in short interest in July. As of July 31st, there was short interest totaling 4,952,300 shares, anincreaseof98.5% from the July 15th total of 2,494,900 shares. Currently,0.7% of the company's stock are short sold. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days. Currently,0.7% of the company's stock are short sold.

Pharming Group Stock Performance

Shares of OTCMKTS PHGUF remained flat at $1.16 during mid-day trading on Friday. Pharming Group has a 12-month low of $0.75 and a 12-month high of $1.19. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.00 and a current ratio of 2.76. The firm's 50-day simple moving average is $1.15 and its 200 day simple moving average is $1.00.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.